Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

Inclusion Criteria: * Kellgren Lawrence (KL) radiological Grade of 2 to 4 in the target knee * Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore of greater than or equal to (\>=) 40 out of 100 in the target knee at screening * Primary or post-traumatic femorotibial OA according to American College of Rheumatology clinical and radiographic criteria * Have completed at least 4 days of the participant 7-day diary in the period from Day -8 to Day 1 * Can give signed informed consent * Other protocol defined inclusion criteria could apply Exclusion Criteria: * History of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening * Intention of having major knee surgeries or total knee replacement during the time frame of this study in either knee * Secondary OA in target knee joint because of joint dysplasia, aseptic osteonecrosis, acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis, or calcium pyrophosphate deposition disease * Any known active systemic infection, including infection that might compromise the immune system such as human immunodeficiency virus, or hepatitis B or C * History of myocardial infarction or cerebrovascular event within 6 months prior to screening, or current active angina pectoris, symptomatic heart failure, seizures, untreated hypertension, gastrointestinal bleeding, or any other significant medical condition in the Investigator's opinion * History of cancer, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ/cervical intraepithelial neoplasia of the uterine cervix, unless considered cured \>= 5 years * Other protocol defined exclusion criteria could apply